Rennova Health, Inc. - Quarter Report: 2005 June (Form 10-Q)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One) |
[X] QUARTERLY REPORT
PURSUANT TO SECTION 13 OR 15(d)OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2005
or
[ ]
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF
THE SECURITIES EXCHANGE ACT OF
1934
Commission File Number: 0-26824
TEGAL CORPORATION
(Exact Name of
Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation or organization) |
68-0370244 (I.R.S. Employer Identification No.) |
2201 South McDowell
Blvd.
Petaluma, California
94954
(Address of
Principal Executive Offices)
Telephone Number (707)
763-5600
(Registrants
Telephone Number, Including Area Code)
_________________
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports) and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange List. Yes [ ] No [X]
As of August 9, 2005 there were 59,404,613 shares of our common stock outstanding.
TEGAL CORPORATION AND SUBSIDIARIES
INDEX
PART I. FINANCIAL INFORMATION | Page | |
---|---|---|
ITEM 1. | CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) | |
Condensed Consolidated Balance Sheets as of June 30, 2005 and March 31, 2005 | 3 | |
Condensed Consolidated Statements of Operations-- for the three months ended June 30, 2005 and 2004 | 4 | |
Condensed Consolidated Statements of Cash Flows-- for the three months ended June 30, 2005 and 2004 | 5 | |
Notes to Condensed Consolidated Financial Statements | 7 | |
ITEM 2. | MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 14 |
ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 24 |
ITEM 4. | CONTROLS AND PROCEDURES | 24 |
PART II. OTHER INFORMATION | ||
---|---|---|
ITEM 1. | LEGAL PROCEEDINGS | 24 |
ITEM 6. | EXHIBITS | 25 |
SIGNATURES | 26 |
PART I FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
TEGAL CORPORATION AND
SUBSIDIARIES
CONDENSED CONSOLIDATED
BALANCE SHEETS
(Unaudited)
(In thousands, except
share and per share data)
June 30, 2005 |
March 31, 2005 | |||||||
---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 3,198 | $ | 7,093 | ||||
Accounts receivable, net of allowances for sales returns and doubtful accounts of $539 and $533 at | ||||||||
June 30, and March 31, 2005 respectively | 2,767 | 1,897 | ||||||
Inventories | 5,957 | 5,140 | ||||||
Prepaid expenses and other current assets | 703 | 641 | ||||||
Total current assets | 12,625 | 14,771 | ||||||
Property and equipment, net | 3,169 | 3,342 | ||||||
Intangible assets, net | 1,715 | 1,796 | ||||||
Other assets | 171 | 183 | ||||||
Total assets | $ | 17,680 | $ | 20,092 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Current liabilities: | ||||||||||||
Notes payable and bank lines of credit | $ | 83 | $ | 159 | ||||||||
Accounts payable | 3,653 | 3,607 | ||||||||||
Accrued product warranty | 238 | 252 | ||||||||||
Deferred revenue | 278 | 122 | ||||||||||
Accrued expenses and other current liabilities | 2,186 | 2,575 | ||||||||||
Total current liabilities | 6,438 | 6,715 | ||||||||||
Long-term portion of capital lease obligations | 13 | 13 | ||||||||||
Other long term obligations | 52 | 64 | ||||||||||
Total long term liabilities | 65 | 77 | ||||||||||
Total liabilities | 6,503 | 6,792 | ||||||||||
Commitments and contingencies (Note 6) | ||||||||||||
Stockholders' equity: | ||||||||||||
Preferred stock; $0.01 par value; 5,000,000 shares authorized; none issued and outstanding | | | ||||||||||
Common stock; $0.01 par value; 100,000,000 shares authorized; 53,019,613 and 52,843,520 shares issued | ||||||||||||
and outstanding at June 30, 2005 and March 31, 2005 respectively | 531 | 528 | ||||||||||
Additional paid-in capital | 99,363 | 99,156 | ||||||||||
Accumulated other comprehensive income (loss) | 64 | (110 | ) | |||||||||
Accumulated deficit | (88,781 | ) | (86,274 | ) | ||||||||
Total stockholders' equity | 11,177 | 13,300 | ||||||||||
Total liabilities and stockholders' equity | $ | 17,680 | $ | 20,092 | ||||||||
See accompanying notes.
TEGAL CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except
per share data)
Three Months Ended June 30, | |||||||||
---|---|---|---|---|---|---|---|---|---|
2005 | 2004 | ||||||||
Revenue: | |||||||||
Product | $ | 2,716 | $ | 3,034 | |||||
Services | 336 | 407 | |||||||
Total revenue | 3,052 | 3,441 | |||||||
Cost of revenue: | |||||||||
Cost of product | 1,724 | 2,177 | |||||||
Cost of services | 653 | 464 | |||||||
Total cost of revenue | 2,377 | 2,641 | |||||||
Gross profit | 675 | 800 | |||||||
Operating expenses: | |||||||||
Research and development | 1,176 | 1,126 | |||||||
Sales and marketing | 644 | 650 | |||||||
General and administrative | 1,240 | 1,601 | |||||||
In-process research and development | | 1,653 | |||||||
Total operating expenses | 3,060 | 5,030 | |||||||
Operating loss | (2,385 | ) | (4,230 | ) | |||||
Other income (expense), net | (122 | ) | (2,095 | ) | |||||
Net loss | $ | (2,507 | ) | $ | (6,325 | ) | |||
Net loss per share, basic and diluted | $ | (0.05 | ) | $ | (0.15 | ) | |||
Shares used in per share computations: | |||||||||
Basic | 52,902 | 41,812 | |||||||
Diluted | 52,902 | 41,812 |
See accompanying notes.
TEGAL CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
Three Months Ended June 30, | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
2005 | 2004 | |||||||||
Cash flows from operating activities: | ||||||||||
Net loss | $ | (2,507 | ) | $ | (6,325 | ) | ||||
Adjustments to reconcile net loss to cash used in operating activities: | ||||||||||
Depreciation and amortization | 339 | 338 | ||||||||
Allowance for doubtful accounts and sales return allowances | (3 | ) | 14 | |||||||
Non cash interest expense - accretion of debt discount and amortization of debt issuance costs | | 2,019 | ||||||||
In-process research and development | | 1,653 | ||||||||
Issuance of options for services rendered | 84 | 39 | ||||||||
Changes in operating assets and liabilities: | ||||||||||
Receivables | (778 | ) | 1,727 | |||||||
Inventories | (733 | ) | 269 | |||||||
Prepaid expenses and other assets | (46 | ) | 193 | |||||||
Accounts payable | 53 | 121 | ||||||||
Accrued product warranty | (5 | ) | (58 | ) | ||||||
Accrued expenses and other liabilities | (392 | ) | (152 | ) | ||||||
Deferred revenue | 156 | (260 | ) | |||||||
Net cash used in operating activities | $ | (3,832 | ) | $ | (422 | ) | ||||
Cash flows from investing activities: | ||||||||||
Purchases of property and equipment | $ | (84 | ) | $ | (20 | ) | ||||
Net cash used in investing activities | $ | (84 | ) | $ | (20 | ) | ||||
Cash flows from financing activities: | ||||||||||
Proceeds from the issuance of common stock | $ | 126 | $ | 335 | ||||||
Borrowings under lines of credit | 34 | 43 | ||||||||
Repayment of borrowings under lines of credit | (110 | ) | (2,297 | ) | ||||||
Payments on capital lease financing | (3 | ) | (5 | ) | ||||||
Net cash (used in) provided by financing activities | $ | 47 | $ | (1,924 | ) | |||||
Effect of exchange rates on cash and cash equivalents | (26 | ) | (26 | ) | ||||||
Net decrease in cash and cash equivalents | $ | (3,895 | ) | $ | (2,392 | ) | ||||
Cash and cash equivalents at beginning of period | $ | 7,093 | $ | 7,049 | ||||||
Cash and cash equivalents at end of period | $ | 3,198 | $ | 4,657 | ||||||
See accompanying notes.
Supplemental Schedule of Non Cash Investing Activities (In thousands, except share data):
On May 28, 2004, Tegal purchased substantially all of the assets and assumed certain liabilities of First Derivative Systems, Inc. (FDSI), a development stage company, for 1,410,632 shares of common stock valued at $2,342, $150 in debt forgiveness, approximately $50 in assumed liabilities, and $158 in acquisition costs. The following table represents the allocation of the purchase price for FDSI. In estimating the fair value of assets acquired and liabilities assumed management considered various factors, including an independent appraisal.
Fair value fixed assets acquired | $ | 111 | |||
Non compete agreements | 203 | ||||
Patents | 733 | ||||
In-process research and development | 1,653 | ||||
Debt forgiveness | (150 | ) | |||
Assumed liabilities | (50 | ) | |||
$ | 2,500 | ||||
See accompanying notes.
TEGAL CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(All amounts in
thousands, except share data)
1. Basis of Presentation:
In the opinion of management, the unaudited condensed consolidated interim financial statements have been prepared on the same basis as the March 31, 2005 audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, necessary to fairly state the information set forth herein. The statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the SEC), but omit certain information and footnote disclosures necessary to present the statements in accordance with generally accepted accounting principles. These interim financial statements should be read in conjunction with the consolidated financial statements and footnotes included in the Companys Annual Report on Form 10-K for the fiscal year ended March 31, 2005. The results of operations for the three months ended June 30, 2005 are not necessarily indicative of results to be expected for the entire year.
The consolidated financial statements contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. The Company incurred net losses of $2,507 and $6,325 for the periods ended June 30, 2005 and 2004, respectively, generated negative cash flows from operations of $3,832 and $422 in these periods, and has a cash and cash equivalents balance of $3,198 at June 30, 2005. During 2005, the Company raised $10,380 from stock issued to Kingsbridge. Management believes that these proceeds, combined with a projected increase in sales, consolidation of certain operations and continued cost containment will be adequate to fund operations through fiscal year 2006. However, projected sales may not materialize and unforeseen costs may be incurred. If the projected sales do not materialize, the Company will need to reduce expenses further and raise additional capital through the issuance of debt or equity securities. If additional funds are raised through the issuance of preferred stock or debt, these securities could have rights, privileges or preferences senior to those of common stock, and debt covenants could impose restrictions on the Companys operations. The sale of equity or debt could result in additional dilution to current stockholders, and such financing may not be available to the Company on acceptable terms, if at all. The failure to raise additional funds may adversely affect the Companys ability to achieve its intended business objectives. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amount or classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern. These factors raise substantial doubt about the Companys ability to continue as a going concern.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of temporary cash investments and accounts receivable. Substantially all of the Companys temporary investments are invested in highly liquid money market funds. The Companys accounts receivables are derived primarily from sales to customers located in the United States, Europe and Asia. The Company performs ongoing credit evaluations of its customers and generally requires no collateral. The Company maintains reserves for potential credit losses. Write-offs during the periods presented have been insignificant. As of June 30, 2005, three customers accounted for approximately 70% of the accounts receivable balance. As of June 30, 2004, two customers accounted for approximately 38% of the accounts receivable balance.
During the quarter ended June 30, 2005, three customers accounted for 63% of total revenues. During the quarter ended June 30, 2004, two customers accounted for 34% of total revenues.
Stock Based Compensation
The Company accounts for stock-based employee compensation under the recognition and measurement principles of Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, (APB No. 25) and related interpretations. Under APB No. 25, compensation cost is equal to the difference, if any, on the date of grant between the fair value of the Companys stock and the amount an employee must pay to acquire the stock. SFAS No. 123, Accounting for Stock-based Compensation, established accounting and disclosure requirements using a fair value based method of accounting for stock-based employee compensation plans. As allowed by SFAS No. 123, the Company has elected to continue to apply the intrinsic value based method of accounting described above, and has adopted the disclosure requirements of SFAS No. 123 and related SFAS No. 148, Accounting for Stock-Based Compensation Transition and Disclosure.
The following assumptions are included in the estimated grant date fair value calculations for the Companys stock option awards and Employee Qualified Stock Purchase Plan (Employee Stock Purchase Plan):
Three Months Ended June 30, 2005 | |||||
---|---|---|---|---|---|
Expected life (years): | |||||
Stock options | 4 | .0 | |||
Employee plan | 4 | .0 | |||
Volatility: | |||||
Stock options | 71 | % | |||
Employee plan | 71 | % | |||
Risk-free interest rate | 3 | .21 | |||
Dividend yield | 0 | % |
The following table illustrates the effect on net income (loss) and net income (loss) per share if the Company had applied the fair value recognition provisions of SFAS No. 123 to stock-based compensation (in thousands, except per share data):
Three Months Ended June 30, | ||||||||
---|---|---|---|---|---|---|---|---|
2005 | 2004 | |||||||
Net loss as reported | $ | (2,507 | ) | $ | (6,325 | ) | ||
Deduct: Total stock-based employee compensation expense | (546 | ) | (358 | ) | ||||
determined under fair value method for all awards, net of tax | ||||||||
Pro forma net loss | $ | (3,053 | ) | $ | (6,683 | ) | ||
Basic net loss per share: | ||||||||
As reported | $ | (0.05 | ) | $ | (0.15 | ) | ||
Pro forma | $ | (0.06 | ) | $ | (0.16 | ) | ||
During the previous fiscal year, the Company entered into a contract with certain consultants for the Company to issue warrants on a monthly basis in lieu of cash payments for the next two years, dependant upon the continuation of the contract and the achievement of certain performance goals. These warrants will be valued and expensed on a monthly basis upon issuance. During the quarter ending June 30, 2005, the Company issued warrants to purchase 84,999 shares of the Companys common stock to service providers for services rendered. The warrants were valued at $84 using the Black-Scholes model with an exercise price at the market value on the day of the grant. The life of the warrants is five and seven years with an interest rate of 2.225% and the volatility of 115% and 118%, respectively.
The disclosure provisions of SFAS No. 123 and SFAS No. 148 require judgments by management as to the estimated lives of the outstanding options. Management has based the estimated life of the options on historical option exercise patterns. If the estimated life of the options increases, the valuation of the options will increase as well.
Accounts Receivable Allowance for Sales Returns and Doubtful Accounts
The Company maintains an allowance for doubtful accounts receivable for estimated losses resulting from the inability of the Companys customers to make required payments. If the financial condition of the Companys customers were to deteriorate, or even a single customer was otherwise unable to make payments, additional allowances may be required.
The Companys return policy is for spare parts and components only. A right of return does not exist for systems. Customers are allowed to return spare parts if they are defective upon receipt. The potential returns are offset against gross revenue on a monthly basis. Management reviews outstanding requests for returns on a quarterly basis to determine that the reserves are adequate.
Impairment of Long-Lived Assets
Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If undiscounted expected future cash flows are less than the carrying value of the assets, an impairment loss is recognized based on the excess of the carrying amount over the fair value of the assets.
Accounting for Freight Charged to Customers
Spares and systems are typically shipped freight collect, therefore no shipping revenue or cost is associated with the sale. When freight is charged, it is booked to revenue and offset for the cost of that freight in the cost of revenue accounts pursuant to FASBs Emerging Issues Task Force (EITF) 00-10.
Revenue Recognition
Each sale of our equipment is evaluated on an individual basis in regard to revenue recognition. We have integrated in our evaluation the related interpretative guidance included in Topic 13 of the codification of staff accounting bulletins, and recognize the role of the EITF consensus on Issue 00-21. We first refer to EITF 00-21 in order to determine if there is more than one unit of accounting and then we refer to SAB104 for revenue recognition topics for the unit of accounting. We recognize revenue when persuasive evidence of an arrangement exists, the sellers price is fixed or determinable and collectibility is reasonably assured.
For products produced according to our published specifications, where no installation is required or installation is deemed perfunctory and no substantive customer acceptance provisions exist, revenue is recognized when title passes to the customer, generally upon shipment. Installation is not deemed to be essential to the functionality of the equipment since installation does not involve significant changes to the features or capabilities of the equipment or the building of complex interfaces and connections. In addition, the equipment could be installed by the customer or other vendors and generally the cost of installation approximates only 1% of the sales value of the related equipment.
For products produced according to a particular customers specifications, revenue is recognized when the product has been tested and it has been demonstrated that it meets the customers specifications and title passes to the customer. The amount of revenue recorded is reduced by the amount (generally 10%), which is not payable by the customer until installation is completed and final customer acceptance is achieved.
For new products, new applications of existing products, or for products with substantive customer acceptance provisions where performance cannot be fully assessed prior to meeting customer specifications at the customer site, 100% of revenue is recognized upon completion of installation and receipt of final customer acceptance. Since title to goods generally passes to the customer upon shipment and 90% of the contract amount becomes payable at that time, inventory is relieved and accounts receivable is recorded for the entire contract amount. The revenue on these transactions is deferred and recorded as deferred revenue. As of June 30, 2005, deferred revenue as related to systems was $238. We reserve for warranty costs at the time the related revenue is recognized.
Revenue related to sales of spare parts is recognized upon shipment. Revenue related to maintenance and service contracts is recognized ratably over the duration of the contracts. Unearned maintenance and service revenue is included in deferred revenue. As of June 30, 2005, $40 of deferred revenue was related to service contracts.
Our return policy is for spare parts and components only. A right of return does not exist for systems. Customers are allowed to return spare parts if they are defective upon receipt. The potential returns are offset against gross revenue on a monthly basis. Management reviews outstanding requests for returns on a quarterly basis to determine that the reserves are adequate.
2. Inventories:
Inventories are stated at the lower of cost or market, reduced by provisions for excess and obsolescence. Cost is computed using standard cost, which approximates actual cost on a first-in, first-out basis and includes material, labor and manufacturing overhead costs. We estimate the effects of excess and obsolescence on the carrying values of our inventories based upon estimates of future demand and market conditions. We establish provisions for related inventories in excess of production demand. Should actual production demand differ from our estimates, additional inventory write-downs may be required, as was the case in the forth quarter of fiscal 2005. Any excess and obsolete provision is released only if and when the related inventories is sold or scrapped. During the period ending June 30, 2005, $131 of previously reserved inventory was sold.
Inventories for the periods presented consisted of:
June 30, 2005 |
March 31, 2005 | |||||||
---|---|---|---|---|---|---|---|---|
Raw materials | $ | 1,080 | $ | 1,044 | ||||
Work in progress | 3,299 | 2,976 | ||||||
Finished goods and spares | 1,578 | 1,120 | ||||||
$ | 5,957 | $ | 5,140 | |||||
We periodically analyze any systems that are in finished goods inventory to determine if they are suitable for current customer requirements. At the present time, our policy is that, if after approximately 18 months, we determine that a sale will not take place within the next 12 months and the system would be useable for customer demonstrations or training, it is transferred to fixed assets. Otherwise, it is expensed.
3. Product Warranty:
The Company provides warranty on all system sales based on the estimated cost of product warranties at the time revenue is recognized. The warranty obligation is effected by product failure rates, material usage rates, and the efficiency by which the product failure is corrected. Should actual product failure rates, material usage rates and labor efficiencies differ from estimates, revisions to the estimated warranty liability may be required.
Warranty activity for the three-month period ended June 30, 2005 and 2004 was:
Warranty Activity For the three months ended June 30, 2005 |
Warranty Activity For the three months ended June 30, 2004 | |||||||
---|---|---|---|---|---|---|---|---|
Balance at the beginning of the period | $ | 252 | $ | 366 | ||||
Additional warranty accruals for warranties issued during the period | 45 | 133 | ||||||
Settlements made during the period | (59 | ) | (187 | ) | ||||
Balance at the end of the period | $ | 238 | $ | 312 | ||||
Certain of the Companys sales contracts include provisions under which customers would be indemnified by the Company in the event of a third-party claim against the customer for intellectual property rights infringement related to the Companys products. There are no limitations on the maximum potential future payments under these guarantees. The Company has accrued no amounts in relation to these provisions as no such claims have been made and the Company believes it has valid, enforceable rights to the intellectual property embedded in its products.
4. Accounting for Restructure Expenses:
During the fiscal year ended March 31, 2005, the Company recorded a severance charge of approximately $129 related to staff reductions of 19 employees, of which approximately $19 was classified as cost of sales, $18 as research and development and $92 as sales, marketing and general and administrative expenses. The Company had an outstanding severance liability of approximately $8 as of June 30, 2005.
5. Net Loss Per Common Share:
Basic earnings per share (EPS) is calculated by dividing net income (loss) for the period by the weighted average common shares outstanding for that period. Diluted EPS takes into account the number of additional common shares that would have been outstanding if the dilutive potential common shares (common stock equivalents) had been issued.
Common stock equivalents for the three months ended June 30, 2005 and 2004 were 6,728,997 and 8,120,760, respectively, and have been excluded from shares used in calculating diluted loss per share because their effect would be antidilutive.
6. Stock-Based Transactions:
Issuance of Common Stock to Kingsbridge Capital Limited
On February 11, 2004, the Company signed a $25 million equity facility with Kingsbridge Capital, Ltd., a firm that specializes in the financing of small to medium sized technology-based companies. The arrangement allowed the Company to sell shares of its common stock to Kingsbridge at its sole discretion over a 24-month period on a when and if needed basis. Kingsbridge Capital was required under the terms of the arrangement to purchase Company common shares following the effectiveness of a registration statement. The price of the common shares issued under the agreement was based on a discount to the volume-weighted average market price during a specified drawdown period. The Company had no obligation to draw down all or any portion of the commitment.
In connection with the agreement, the Company issued fully vested warrants to Kingsbridge Capital to purchase 300,000 shares of the Companys common stock at an exercise price of $4.11 per share. The fair value of such options, which amounted to approximately $756 was capitalized as a transaction cost. The following variables were used to determine the fair value of such instruments under the Black-Scholes option pricing model: volatility of 114%, term of five years, risk free interest of 3.91% and underlying stock price equal to fair market value at the time of grant.
During the fiscal year end March 31, 2005, the Company issued to Kingsbridge Capital a total of 8,506,331 shares of its common stock in connection with the Amended and Restated Common Stock Purchase Agreement dated as of May 19, 2004. Gross proceeds from the sale of stock were $10,380. The discount to the volume-weighted average market price was $1,153 that was charged against equity as stock issuance cost. In addition to $623 in cash payments, the Company issued warrants to purchase 23,727, 21,686 24,092 and 15,549 shares of common stock at $1.45, $1.56, $1.92 and $1.35 respectively, to advisors, in connection with the sale of stock to Kingsbridge which were charged against equity as stock issuance costs. Pursuant to our agreement, broker fees of 6% in cash and 1% of stock in the form of warrants were paid upon each drawdown of the facility. Additionally, warrants issued at the time of the agreement were held in current assets and have been fully amortized as of March 31, 2005 and charged against equity as stock issuance costs. The Company does not anticipate any further sales of shares to Kingsbridge under the agreement.
The selling price of the stock was negotiated as a function of market price based on a specific formula. Pursuant to C08 Capital Stock Transactions the discount was accounted for as a cost of capital and netted against Additional Paid in Capital. Since the transaction was related to the sale of our own common stock, it was excluded from the determination of net income.
Issuance of Warrants to Consultants
The Company is party to a contract with certain consultants pursuant to which the Company will issue warrants on a monthly basis in lieu of cash payments through August 2006, depending upon the continuation of the contract and the achievement of certain performance goals. The maximum number of warrants to be issued under these agreements is 990,000 shares. During the three months ended June 30, 2005, the warrants were valued at $84 using the Black-Scholes model with an exercise price at the market value on the day of the grant. The life of the warrants are five and seven years with an interest rate of 2.225% and volatility of 118% and 115% respectively. None of these warrants have been exercised as of June 30, 2005.
7. Lines of Credit:
As of June 30, 2005, the Companys Japanese subsidiary had borrowed 3.9 million Yen (approximately $35 at exchange rates prevailing on June 30, 2005) under its Japanese bank line of credit. The credit line has a total borrowing capacity of 150 million Yen (approximately $1,351 at exchange rates prevailing on June 30, 2005), which is secured by Japanese customer promissory notes held by such subsidiary in advance of payment on customers accounts receivable. The Japanese bank line bears interest at Japanese prime (1.375% as of June 30, 2005) plus 0.875%.
Notes payable as of June 30, 2005 consisted primarily of one outstanding note to the California Trade and Commerce Agency for $48. The unsecured note from the California Trade and Commerce Agency carries an annual interest rate of 5.75% with monthly payments of approximately $5.5 per month. Although the payment deadlines are being met, the note is currently in technical default due to the merger of Sputtered Films and Tegal Corporation.
8. Geographical Information
Tegal operates in one segment for the manufacture, marketing and servicing of integrated circuit fabrication equipment. In accordance with SFAS No. 131 (SFAS 131) Disclosures About Segments of an Enterprise and Related Information, Tegals chief operating decision-maker has been identified as the President and Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire company. All material operating units qualify for aggregation under SFAS 131 due to their identical customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since Tegal operates in one segment and in one group of similar products and services, all financial segment and product line information required by SFAS 131 can be found in the consolidated financial statements.
For geographical reporting, revenues are attributed to the geographic location in which the customers facilities are located. Long-lived assets consist primarily of property, plant and equipment, and are attributed to the geographic location in which they are located. Net sales and long-lived assets by geographic region were as follows:
Revenue for the Three Months Ended June 30, | ||||||||
---|---|---|---|---|---|---|---|---|
2005 | 2004 | |||||||
Sales to customers located in: | ||||||||
United States | $ | 327 | $ | 1,186 | ||||
Asia, excluding Japan | 140 | 364 | ||||||
Japan | 578 | 1,372 | ||||||
Europe | 2,007 | 519 | ||||||
Total sales | 3,052 | 3,441 | ||||||
June 30, 2005 |
March 31, 2005 | |||||||
---|---|---|---|---|---|---|---|---|
Long-lived assets at period-end: | ||||||||
United States | $ | 4,857 | $ | 5,112 | ||||
Europe | 5 | 7 | ||||||
Japan | 19 | 16 | ||||||
Asia, excluding Japan | 2 | 3 | ||||||
Total long-lived assets | $ | 4,883 | $ | 5,138 | ||||
9. Comprehensive Income (Loss):
The components of comprehensive loss for the three-month periods ended June 30, 2005 and 2004 are as follows:
Three Months Ended June 30, | ||||||||
---|---|---|---|---|---|---|---|---|
2005 | 2004 | |||||||
Net loss | $ | (2,507 | ) | $ | (6,325 | ) | ||
Foreign currency translation adjustment | 174 | 24 | ||||||
$ | (2,333 | ) | $ | (6,301 | ) | |||
10. Acquisition:
On May 28, 2004, Tegal purchased substantially all of the assets and assumed certain liabilities of First Derivative Systems, Inc. (FDSI), a development stage company, for 1,410,632 shares of common stock valued at $2,342, $150 in debt forgiveness, approximately $50 in assumed liabilities, and $158 in acquisition costs. In addition, the Company entered into employment agreements with key FDSI personnel. This transaction was accounted for as a purchase of assets in accordance with EITF Issue No. 98-3, Determining whether a nonmonetary transaction involves receipt of productive assets or of a business.
The following table represents the allocation of the purchase price for FDSI. The purchase price of this acquisition has been allocated to the acquired assets and assumed liabilities on the basis of their fair values as of the date of the acquisition. In estimating the fair value of the assets acquired and liabilities assumed, management considered various factors, including an independent appraisal.
Fair value fixed assets acquired | $ | 111 | |||
Non compete agreements | 203 | ||||
Patents | 733 | ||||
In-process research and development | 1,653 | ||||
Debt forgiveness | (150 | ) | |||
Assumed liabilities | (50 | ) | |||
$ | 2,500 | ||||
The assets will be amortized over a period of years shown on the following table:
Fixed assets acquired | 3 to 5 years | ||||
Non compete agreements | 3 years | ||||
Patents | 15 years |
The fair value underlying the $1,653 assigned to acquired in-process research and development (IPR&D) in the FDSI acquisition was charged to the Companys results of operations during the quarter ended June 30, 2004, and was determined by identifying research projects in areas for which technological feasibility had not been established and there was no alternative future use. Projects in the IPR&D category are primarily certain design change improvements, software integration and hardware modifications, which are estimated to cost approximately $1 $2 million, are approximately 50% complete, and will be completed by December 31, 2005.
The IPR&D value of $1,653 was determined by an income approach where fair value is the present value of projected free cash flows that will be generated by the products incorporating the acquired technologies under development, assuming they are successfully completed. The estimated net free cash flows generated by the products over a seven-year period were discounted at a rate of 35% in relation to the stage of completion and the technical risks associated with achieving technological feasibility. The net cash flows for such projects were based on managements estimates of revenue, expenses and asset requirements. Any delays or failures in the completion of these projects could impact expected return on investment and future results of operations. In addition, the Companys operating results would be adversely affected if the value of other intangible assets acquired became impaired.
All of these projects have completion risks related to functionality, architecture, performance, process technology, continued availability of key technical personnel, product reliability and software integration. To the extent that estimated completion dates are not met, the risk of competitors product introductions is greater and revenue opportunity may be permanently lost.
11. 2% Convertible Debentures:
During fiscal year ended March 31, 2004, the Company raised $7,165 in a private placement of convertible debt financing. The Company was required to pay a cash fee of up to 6.65% of the gross proceeds of the debentures to certain financial advisors along with warrants to purchase 1,756,127 shares of the Companys common stock at an exercise price of $0.35 per share. These warrants were valued at $1,387 using the Black-Scholes option pricing model with the following variables: stock fair value of $0.93, term of five years, volatility of 95% and risk-free interest rate of 2.5%. Advisor warrants for 196,129 shares remain outstanding at June 30, 2005.
The debentures accrued interest at the rate of 2% per annum. Both the principal and accrued interest thereon of these debentures were convertible at the rate of $0.35 per share. The principal of the debentures converted into 20,471,428 shares of the Companys common stock. The closing prices of the Companys common stock on June 30, 2003 and September 9, 2003, the closing dates for the first and second tranches, were $0.55 and $1.49. Therefore, a beneficial conversion feature existed which was accounted for under the provisions of EITF 00-27, Application of Issue 98-5 to Certain Convertible Instruments. A beneficial feature also existed in connection with the conversion of the interest on the debentures into shares of common stock.
As of June 30, 2004, debenture holders had converted all the debentures in the principal amount of $7,165 into 20,471,428 shares of the Companys common stock. Of the 3,542,436 shares that were registered for payment of interest in-kind, 135,068 shares had been issued for such interest payments, and the interest obligation to the debenture holders had been satisfied in full.
In addition, the debenture holders were granted warrants to purchase 4,094,209 shares of the Companys common stock at an exercise price of $0.50. The warrants expire after eight years. The warrants were valued using the Black-Scholes model with the following variables: fair value of common stock of $0.35 for the first tranche debentures and $0.93 for the second tranche debentures, volatility of 37% and risk-free interest rate of 2.5%. As of June 30, 2005, there remained unexercised warrants held by the debenture holders for 1,521,940 shares of the Companys common stock.
12. Subsequent Event:
On July 6, 2005, the Company entered into a Purchase Agreement pursuant to which the Company sold at an initial closing, and plans to sell in a second closing, unregistered shares of its common stock, par value $0.01 per share, and warrants exercisable for Common Stock to the investors identified in the Purchase Agreement. All of the securities were sold and will be sold, in a private placement pursuant to Regulation D of the Securities Act of 1933, as amended (the Act), solely to accredited investors, as defined in Rule 501 of the Act.
Purchase Agreement. Pursuant to the Purchase Agreement, the Company agreed to sell approximately 6.3 million shares of common stock and warrants exercisable for up to approximately 3.15 million additional shares of common stock for aggregate gross cash proceeds of approximately $4.1 million at the initial closing on July 14, 2005. In addition, subject to stockholder approval, the Company agreed to sell approximately 28.3 million additional shares of common stock and warrants exercisable for up to approximately 14.2 million additional shares of common stock for aggregate gross cash proceeds of approximately $18.4 million at a second closing expected to occur after the Companys annual stockholder meeting currently scheduled to be held on September 13, 2005. The common stock , the warrants and the shares of common stock issuable upon exercise of the warrants will be restricted securities as that term is defined in the Act.
Registration Rights Agreement. At the initial closing, the Company entered into a registration rights agreement to register for resale by the investors the shares of common stock sold and the shares issuable upon the exercise of the warrants. Pursuant to the agreement, the Company will file with the Securities and Exchange Commission a registration statement covering these shares. The fees and expenses of such registration will be borne by the Company, and the agreement will include customary indemnification provisions.
Warrants. The warrants issued to each investor is exercisable for up to 50% of the number of shares of common stock purchased by such investor pursuant to the Purchase Agreement at an exercise price of $1.00 per share. The exercise price and number of shares issuable upon exercise of the warrants are subject to adjustment in the event of stock dividends, stock splits, dilutive issuances and other similar events. The warrants have a term of five years, are be fully exercisable from the date of issuance, and may be exercised on a cashless basis under specified conditions.
In connection with the initial closing, the Company paid a placement fee of $286,650 (equal to 7% of the Companys gross proceeds from the initial closing) to Dahlman Rose & Company LLC, the Companys financial advisor. The Company will also pay Dahlman Rose & Company LLC a placement fee equal to 7% of the Companys gross proceeds from the second closing.
Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
Information herein contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which can be identified by the use of forward-looking terminology such as may, will, expect, anticipate, estimate, or continue or the negative thereof or other variations thereon or comparable terminology or which constitute projected financial information. The forward-looking statements relate to the near-term semiconductor capital equipment industry outlook, demand for our products, our quarterly revenue and earnings prospects for the near-term future and other matters contained herein. Such statements are based on current expectations and beliefs and involve a number of uncertainties and risks that could cause the actual results to differ materially from those projected. Such uncertainties and risks include, but are not limited to, the consummation of the second closing of our recent financing, which requires stockholder approval, cyclicality of the semiconductor industry, impediments to customer acceptance of our products, fluctuations in quarterly operating results, competitive pricing pressures, the introduction of competitor products having technological and/or pricing advantages, product volume and mix and other risks detailed from time to time in our SEC reports. For further information, refer to the business description and risk factors sections included in our Form 10-K for the year ended March 31, 2005 and the risk factors section included in this Form 10-Q (Part II, Item 5) as filed with the SEC.
The following summarizes our contractual obligations at June 30, 2005, and the effect such obligations are expected to have on our liquidity and cash flows in future periods (in thousands).
Contractual obligations: | Total | Less than 1 Year |
1-3 Years | 3-5 Years | After 5 Years | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Non-cancelable capital lease obligations | $ | 23 | $ | 10 | $ | 13 | $ | $ | | ||||||||
Non-cancelable operating lease obligations | 5,135 | 1,402 | 2,221 | 1,512 | | ||||||||||||
Notes payable and bank lines of credit, | 83 | 83 | | | | ||||||||||||
Total contractual cash obligations | $ | 5,241 | $ | 1,495 | $ | 2,234 | $ | 1,512 | $ | |
Certain sales contracts of the Company include provisions under which customers would be indemnified by the Company in the event of, among other things, a third-party claim against the customer for intellectual property rights infringement related to the Companys products. There are no limitations on the maximum potential future payments under these guarantees. The Company has accrued no amounts in relation to these provisions as no such claims have been made and the Company believes it has valid, enforceable rights to the intellectual property embedded in its products.
Critical Accounting Policies
Our discussion and analysis of the financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to inventory, warranty obligations, purchase order commitments, bad debts, income taxes, intangible assets, restructuring and contingencies and litigation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements:
Revenue Recognition
Each sale of our equipment is evaluated on an individual basis in regard to revenue recognition. We have integrated in our evaluation the related interpretative guidance included in Topic 13 of the codification of staff accounting bulletins, and recognize the role of the FASBs Emerging Issues Task Force (EITF) consensus on Issue 00-21. We first refer to EITF 00-21 in order to determine if there is more than one unit of accounting and then we refer to SAB104 for revenue recognition topics for the unit of accounting. We recognize revenue when persuasive evidence of an arrangement exists, the sellers price is fixed or determinable and collectibility is reasonably assured.
For products produced according to our published specifications, where no installation is required or installation is deemed perfunctory and no substantive customer acceptance provisions exist, revenue is recognized when title passes to the customer, generally upon shipment. Installation is not deemed to be essential to the functionality of the equipment since installation does not involve significant changes to the features or capabilities of the equipment or building complex interfaces and connections. In addition, the equipment could be installed by the customer or other vendors and generally the cost of installation approximates only 1% of the sales value of the related equipment.
For products produced according to a particular customers specifications, revenue is recognized when the product has been tested and it has been demonstrated that it meets the customers specifications and title passes to the customer. The amount of revenue recorded is reduced by the amount (generally 10%), which is not payable by the customer until installation is completed and final customer acceptance is achieved.
For new products, new applications of existing products, or for products with substantive customer acceptance provisions where performance cannot be fully assessed prior to meeting customer specifications at the customer site, 100% of revenue is recognized upon completion of installation and receipt of final customer acceptance. Since title to goods generally passes to the customer upon shipment and 90% of the contract amount becomes payable at that time, inventory is relieved and accounts receivable is recorded for the entire contract amount. The revenue on these transactions is deferred and recorded as deferred revenue. We reserve for warranty costs at the time the related revenue is recognized.
Revenue related to sales of spare parts is recognized upon shipment. Revenue related to maintenance and service contracts is recognized ratably over the duration of the contracts. Unearned maintenance and service revenue is included in other accrued liabilities.
Accounts Receivable Allowance for Sales Returns and Doubtful Accounts
We maintain an allowance for doubtful accounts receivable for estimated losses resulting from the inability of our customers to make required payments. If the financial condition of our customers were to deteriorate, or even a single customer was otherwise unable to make payments, additional allowances may be required.
Our return policy is for spare parts and components only. A right of return does not exist for systems. Customers are allowed to return spare parts if they are defective upon receipt, in accordance with SFAS 48. The potential returns are offset against gross revenue on a monthly basis. Management reviews outstanding requests for returns on a quarterly basis to determine that the reserves are adequate.
Inventories
Inventories are stated at the lower of cost or market, reduced by provisions for excess and obsolescence. Cost is computed using standard cost, which approximates actual cost on a first-in, first-out basis and includes material, labor and manufacturing overhead costs. We estimate the effects of excess and obsolescence on the carrying values of our inventories based upon estimates of future demand and market conditions. We establish provisions for related inventories in excess of production demand. Should actual production demand differ from our estimates, additional inventory write-downs may be required, as was the case in the forth quarter of fiscal 2005. Any excess and obsolete provision is released only if and when the related inventories is sold or scrapped.
We periodically analyze any systems that are in finished goods inventory to determine if they are suitable for current customer requirements. At the present time, our policy is that, if after approximately 18 months, we determine that a sale will not take place within the next 12 months, and the system would be useable for customer demonstrations or training, it is transferred to fixed assets. Otherwise, it is expensed.
The carrying value of systems used for demonstrations or training is determined by assessing the cost of the components that are suitable for sale. Any parts that may be rendered unsaleable as a result of such use are removed from the system and are not included in finished goods inventory. The remaining saleable parts are valued at the lower of cost or market, representing the systems net realizable value. The depreciation period for systems that are transferred to fixed assets is determined based on the age of the system and its remaining useful life (typically five to eight years).
Impairment of Long-Lived Assets
Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If undiscounted expected future cash flows are less than the carrying value of the assets, an impairment loss is recognized based on the excess of the carrying amount over the fair value of the assets.
Warranty Obligations
We provide for the estimated cost of our product warranties at the time revenue is recognized. Our warranty obligation is affected by product failure rates, material usage rates and the efficiency by which the product failure is corrected. Should actual product failure rates, material usage rates and labor efficiencies differ from our estimates, revisions to the estimated warranty liability may be required.
Deferred Taxes
We record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. Based on the uncertainty of future taxable income, we have fully reserved our deferred tax assets. In the event we were to determine that we would be able to realize our deferred tax assets in the future, an adjustment to the deferred tax asset would increase income in the period such determination was made.
Results of Operations
Tegal designs, manufactures, markets and services plasma etch and deposition systems that enable the production of integrated circuits (ICs), memory and related microelectronics devices used in personal computers, wireless voice and data telecommunications, contact-less transaction devices, radio frequency identification devices (RFIDs), smart cards, data storage and micro-level actuators. Etching and deposition constitute two of the principal IC and related device production process steps and each must be performed numerous times in the production of such devices.
Three Months Ended June 30, | ||||||||
---|---|---|---|---|---|---|---|---|
2005 | 2004 | |||||||
Revenue: | ||||||||
Product revenue | 89 | .0% | 88 | .2% | ||||
Services revenue | 11 | .0 | 11 | .8 | ||||
Total revenue | 100 | .0 | 100 | .0 | ||||
Cost of sales: | ||||||||
Cost of product | 56 | .5 | 63 | .3 | ||||
Cost of services | 21 | .4 | 13 | .5 | ||||
Total cost of sales | 77 | .9 | 76 | .8 | ||||
Gross profit | 22 | .1 | 23 | .2 | ||||
Operating expenses: | ||||||||
Research and development | 38 | .5 | 32 | .7 | ||||
Sales and marketing | 21 | .1 | 18 | .9 | ||||
General and administrative | 40 | .6 | 46 | .5 | ||||
In-process research and development | 0 | .0 | 48 | .0 | ||||
Total operating expenses | 100 | .2 | 146 | .1 | ||||
Operating loss | (78 | .1) | (122 | .9) | ||||
Other income (expense), net | (4 | .0) | (60 | .9) | ||||
Net loss | (82 | .1)% | (183 | .8)% |
Product Revenue. Revenue for the three months ended June 30, 2005 was $2,716, a decrease of $318 or 10% over the comparable period in 2004. The decrease for the three months ended June 30, 2005 was principally due to reduced sales of spare parts which we believe is a result of reduced usage of our non-critical etch systems by our customers. Revenue for the three months ended June 30, 2004 was $3,034, a decrease of $508 or 14.3% over the comparable period in 2003. The decrease for the three months ended June 30, 2004 was principally due to the sale of a used 6500 series system compared to the sale of a new system in the prior period offset in part by the recognition of deferred revenue in the current period.
Services Revenue. Revenue from service sales was $336 for the three month period ended June 30, 2005, down from $407 for the three month period ended June 30, 2004, which we believe is a result of customers decreased use of our non critical etch systems.
International sales as a percentage of our revenue were approximately 89% and 66% for the three months ended June 30, 2005 and 2004, respectively. We believe that international sales will continue to represent a significant portion of our revenue.
Gross profit. Gross profit as a percentage of revenue (gross margin) was relatively flat at 22% and 23% for the three months ended June 30, 2005 and 2004, respectively.
Research and development. Research and development expenses consist primarily of salaries, prototype material and other costs associated with our ongoing systems and process technology development, applications and field process support efforts. Research and development expenses were relatively flat at $1,176 and $1,126 for the three months ended June 30, 2005 and 2004, respectively, representing 39% and 33% of revenue, respectively.
Sales and marketing. Sales and marketing expenses consist primarily of salaries, commissions, trade show promotion and travel and living expenses associated with those functions. Sales and marketing expenses were relatively flat year over year at $644 and $650 for the three months ended June 30, 2005 and 2004, respectively, representing 21% and 19% of revenue, respectively.
General and administrative. General and administrative expenses consist primarily of compensation for general management, accounting and finance, human resources, information systems and investor relations functions and for legal, consulting and accounting fees of the Company. General and administrative expenses were $1,240 and $1,601 for the three months ended June 30, 2005 and 2004, respectively, representing 41% and 47% of revenue, respectively. The decrease in spending was primarily due to reduced legal and consulting fees.
Other income (expense), net. Other expense, net consists principally of, interest income, interest expense and gains and losses on foreign exchange. We recorded net non-operating expense of $122 and a non-operating income of $2,095 during the three months ended June 30, 2005 and 2004, respectively. The decrease of other expense in the current period was due primarily to interest income for the period ended June 30, 2005 of $10 compared to interest expense of $2,066 during the same period a year ago. The interest expense in the previous year was primarily attributable to the accretion of the debt discount and the amortization of the debt issuance costs related to the debenture financing which was fully converted by June 30, 2004.
Liquidity and Capital Resources
For the three-month periods ended June 30, 2005, we financed our operations through the use of outstanding cash balances and borrowings against our credit facilities in Japan.
Net cash used in operations was $3,832 during the three months ended June 30, 2005, due principally to a net loss of $2,507 with increased accounts receivable and inventory, and decreased accrued liabilities, offset by increased deferred revenue, and non cash expenses from depreciation, amortization, and warrants issued for services rendered.
Capital expenditures were $84 for the three months ended June 30, 2005 and were principally due to expenditures for improvements made on PVD 300 demo lab equipment.
Net cash provided by financing activities totaled $47 for the three months ended June 30, 2005 and was primarily related to the issuance of common stock through the exercise of stock options offset by payments on the credit facility in Japan.
As of June 30, 2005, the Companys Japanese subsidiary had borrowed 3.9 million Yen (approximately $35 at exchange rates prevailing on June 30, 2005) under its Japanese bank line of credit. The credit line has a total borrowing capacity of 150 million Yen (approximately $1,351 at exchange rates prevailing on June 30, 2005), which is secured by Japanese customer promissory notes held by such subsidiary in advance of payment on customers accounts receivable. The Japanese bank line bears interest at Japanese prime (1.375% as of June 30, 2005) plus 0.875%.
Notes payable as of June 30, 2005 consisted primarily of one outstanding note to the California Trade and Commerce Agency for $48. The unsecured note from the California Trade and Commerce Agency carries an annual interest rate of 5.75% with monthly payments of approximately $5.5 per month. Although the payment deadlines are being met, the note is currently in technical default due to the merger of Sputtered Films and Tegal Corporation.
The consolidated financial statements contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. We incurred net losses of $2,507 and $6,325 for the periods ended June 30, 2005 and 2004, respectively, generated negative cash flows from operations of $3,832 and $422 in these periods, and has a cash and cash equivalents balance of $3,198 at June 30, 2005. During fiscal year 2005, we raised $10.4 million from stock issued to Kingsbridge and $4.1 million from the sale of stock and warrants to the selling securityholders. Assuming we obtain stockholder approval, we will issue to the selling securityholders 28,315,385 additional shares of common stock and warrants to purchase an additional 14,157,692 shares of common stock for an aggregate purchase price of $18.4 million. We believe that these proceeds, combined with a projected increase in sales, consolidation of certain operations and continued cost containment will be adequate to fund operations through fiscal year 2006. However, projected sales may not materialize and unforeseen costs may be incurred. If the projected sales do not materialize, we will need to reduce expenses further and raise additional capital through the issuance of debt or equity securities. If additional funds are raised through the issuance of preferred stock or debt, these securities could have rights, privileges or preferences senior to those of common stock, and debt covenants could impose restrictions on our operations. The sale of equity or debt could result in additional dilution to current stockholders. Moreover, such financings may not be available to us on acceptable terms, if at all.
We raised additional capital in July 2005 (see Note 12 to the financial statements), and expect to raise additional capital upon the consummation of the second closing of the July 2005 private placement financing, assuming stockholder approval. The July 2005 private placement will result in significant additional dilution to our stockholders.
The failure to raise additional funds, including the consummation of the second closing of the July 2005 private placement, may adversely affect our ability to achieve our intended business objectives. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amount or classification of liabilities or any other adjustments that might be necessary should we be unable to continue as a going concern. These factors raise substantial doubt about our ability to continue as a going concern.
Risk Factors
Investing in our common stock involves a significant amount of risk. You should carefully consider the following risk factors, in addition to the other information set forth in this 10-Q and incorporated in this 10-Q by reference to our Annual Report on Form 10-K for the fiscal year ended March 31, 2005 and our other filings with the SEC before deciding to purchase our common stock.
We have incurred operating losses and may not be profitable in the future; Our plans to maintain and increase liquidity may not be successful; The report of the independent registered public accounting firm includes a going concern uncertainty explanatory paragraph.
We incurred net losses of $15.4 million, $12.6 million and $12.6 million for the years ended March 31, 2005, 2004 and 2003, respectively, and generated negative cash flows from operations of $7.5 million, $3.2 million and $6.0 million in these respective years. These factors raise substantial doubt as to our ability to continue as a going concern, and our independent registered public accounting firm has included a going concern uncertainty explanatory paragraph in their report dated May 27, 2005 filed with our Annual Report on Form 10-K/A for the year ended March 31, 2005. During fiscal year 2005, we raised $10.4 million from stock issued to Kingsbridge and then another $4.1 million from the sale of stock and warrants to the selling securityholders. Assuming we obtain stockholder approval with respect to the second closing, we will issue to the selling securityholders 28,315,385 additional shares of common stock and warrants to purchase an additional 14,157,692 shares of common stock for an aggregate purchase price of $18.4 million. Management believes that these proceeds, combined with a projected increase in sales, consolidation of certain operations and continued cost containment will be adequate to fund operations through fiscal year 2006. However, these projected sales are to a limited number of new and existing customers and are based, for the most part, on internal and customer provided estimates of future demand, not firm customer orders. If the projected sales do not materialize, we will need to reduce expenses further and raise additional capital through the issuance of debt or equity securities. If additional funds are raised through the issuance of preferred stock or debt, these securities could have rights, privileges or preferences senior to those of our common stock, and debt covenants could impose restrictions on our operations. Moreover, such financing may not be available to us on acceptable terms, if at all. Failure to raise additional funds may adversely affect our ability to achieve our intended business objectives. Our consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amount or classification of liabilities or any other adjustments that might be necessary should we be unable to continue as a going concern.
The exercise of outstanding warrants, options and other rights to obtain additional shares will dilute the value of our shares of common stock and could cause the price of our shares of common stock to decline.
As of July 15, 2005, there were 59,403,299 shares of our common stock issued and outstanding and there were 12,607,873 shares of common stock reserved for issuance under our equity incentive and stock purchase plans.
As of July 15, 2005, there were warrants exercisable for approximately 1,521,940 shares of our common stock, advisor warrants convertible into 196,129 shares, options exercisable for approximately 7,946,527 shares of our common stock. In addition, we have warrants outstanding from previous offerings for approximately 2,510,534 shares of our common stock. Assuming we obtain stockholder approval, at the second closing we will issue an additional 28,315,385 shares of common stock and warrants to purchase an additional 14,157,692 shares of common stock to the selling securityholders. In addition, we are soliciting stockholder approval to increase our number of authorized shares of common stock from 100,000,000 to 200,000,000 shares and to significantly increase the number of shares of common stock available for issuance pursuant to our equity incentive and stock purchase plans by 12,400,000. We may issue additional capital stock, convertible securities and/or warrants to raise capital in the future. In addition, to attract and retain key personnel, we may issue additional securities, including stock options.
The exercise of these warrants and options and the issuance of the common stock will result in dilution in the value of the shares of our outstanding common stock and the voting power represented thereby. In addition, the exercise price of the warrants may be lowered under the price adjustment provisions in the event of a dilutive issuance, that is, if we issue common stock at any time prior to their maturity at a per share price below such conversion or exercise price, either directly or in connection with the issuance of securities that are convertible into, or exercisable for, shares of our common stock. A reduction in the exercise price may result in the issuance of a significant number of additional shares upon the exercise of the warrants.
The warrants do not establish a floor that would limit reductions in such conversion price or exercise price. The downward adjustment of the exercise price of these warrants could result in further dilution in the value of the shares of our outstanding common stock and the voting power represented thereby.
No prediction can be made as to the effect, if any, that future sales of shares of our common stock, or the availability of shares for future sale, will have on the market price of our common stock prevailing from time to time. Sales of substantial amounts of shares of our common stock in the public market, or the perception that such sales could occur, may adversely affect the market price of our common stock and may make it more difficult for us to sell our equity securities in the future at a time and price which we deem appropriate.
To the extent the selling securityholders who have purchased our common shares and the holders of our warrants and options exercise such securities and then sell the shares of our common stock they receive upon exercise, our stock price may decrease due to the additional amount of shares available in the market. The subsequent sales of these shares could encourage short sales by our securityholders and others, which could place further downward pressure on our stock price. Moreover, holders of these warrants may hedge their positions in our common stock by shorting our common stock, which could further adversely affect our stock price.
If we fail to meet the continued listing requirements of the NASDAQ Stock Market, our stock could be delisted.
Our stock is currently listed on The NASDAQ SmallCap Market. The NASDAQ Stock Markets Marketplace Rules impose certain minimum financial requirements on us for the continued listing of our stock. One such requirement is the minimum bid price on our stock of $1.00 per share. Beginning in 2002, there have been periods of time during which we have been out of compliance with the $1.00 minimum bid requirements of The NASDAQ SmallCap Market.
If we are out of compliance in the future with NASDAQ listing requirements, we may take actions in order to achieve compliance, which actions may include a reverse split of our common stock. If an initial delisting decision is made by the NASDAQs staff, we may appeal the decision as permitted by NASDAQ rules. If we are delisted and cannot obtain listing on another major market or exchange, our stocks liquidity would suffer, and we would likely experience reduced investor interest. Such factors may result in a decrease in our stocks trading price. Delisting also may restrict us from issuing additional securities or securing additional financing.
The semiconductor industry is cyclical and may experience periodic downturns that may negatively affect customer demand for our products and result in losses such as those experienced in the past.
Our business depends upon the capital expenditures of semiconductor manufacturers, which in turn depend on the current and anticipated market demand for integrated circuits. The semiconductor industry is highly cyclical and historically has experienced periodic downturns, which often have had a detrimental effect on the semiconductor industrys demand for semiconductor capital equipment, including etch and deposition systems manufactured by us. In response to the current prolonged industry slow-down, we have initiated a substantial cost containment program and completed a corporate-wide restructuring to preserve our cash. However, the need for continued investment in research and development, possible capital equipment requirements and extensive ongoing customer service and support requirements worldwide will continue to limit our ability to reduce expenses in response to the current downturn.
Our competitors have greater financial resources and greater name recognition than we do and therefore may compete more successfully in the semiconductor capital equipment industry than we can.
We believe that to be competitive, we will require significant financial resources in order to offer a broad range of systems, to maintain customer service and support centers worldwide and to invest in research and development. Many of our existing and potential competitors, including, among others, Applied Materials, Inc., Lam Research Corporation, Novellus and Tokyo Electron Limited, have substantially greater financial resources, more extensive engineering, manufacturing, marketing and customer service and support capabilities, larger installed bases of current generation etch, deposition and other production equipment and broader process equipment offerings, as well as greater name recognition than we do. We cannot assure you that we will be able to compete successfully against these companies in the United States or worldwide.
We depend on sales of our advanced products to customers that may not fully adopt our product for production use.
We have designed our advanced etch and deposition products for customer applications in emerging new films, polysilicon and metal which we believe to be the leading edge of critical applications for the production of advanced semiconductor and other microelectronic devices. Revenues from the sale of our advanced etch and deposition systems accounted for 30%, 40% and 25% of total revenues in fiscal 2005, 2004 and 2003, respectively. Our advanced systems are currently being used primarily for research and development activities or low volume production. For our advanced systems to achieve full market adoption, our customers must utilize these systems for volume production. There can be no assurance that the market for devices incorporating emerging films, polysilicon or metal will develop as quickly or to the degree we expect.
If our advanced systems do not achieve significant sales or volume production due to a lack of full customer adoption, our business, financial condition, results of operations and cash flows will be materially adversely affected.
Our potential customers may not adopt our products because of their significant cost or because our potential customers are already using a competitors tool.
A substantial investment is required to install and integrate capital equipment into a semiconductor production line. Additionally, we believe that once a device manufacturer has selected a particular vendors capital equipment, that manufacturer generally relies upon that vendors equipment for that specific production line application and, to the extent possible, subsequent generations of that vendors systems. Accordingly, it may be extremely difficult to achieve significant sales to a particular customer once that customer has selected another vendors capital equipment unless there are compelling reasons to do so, such as significant performance or cost advantages. Any failure to gain access and achieve sales to new customers will adversely affect the successful commercial adoption of our products and could have a detrimental effect on us.
Our quarterly operating results may continue to fluctuate.
Our revenue and operating results have fluctuated and are likely to continue to fluctuate significantly from quarter to quarter, and there can be no assurance as to future profitability.
Our 900 series etch systems typically sell for prices ranging between $250,000 and $600,000 while prices of our 6500 series critical etch systems and our Endeavor deposition system typically range between $1.8 million and $3.0 million. To the extent we are successful in selling our 6500 and Endeavor series systems, the sale of a small number of these systems will probably account for a substantial portion of revenue in future quarters, and a transaction for a single system could have a substantial impact on revenue and gross margin for a given quarter.
Other factors that could affect our quarterly operating results include:
| our timing of new systems and technology announcements and releases and ability to transition between product versions; |
| seasonal fluctuations in sales; |
| changes in the mix of our revenues represented by our various products and customers; |
| adverse changes in the level of economic activity in the United States or other major economies in which we do business; |
| foreign currency exchange rate fluctuations; |
| expenses related to, and the financial impact of, possible acquisitions of other businesses; and |
| changes in the timing of product orders due to unexpected delays in the introduction of our customers' products, due to lifecycles of our customers' products ending earlier than expected or due to market acceptance of our customers' products. |
Our financial performance may adversely affect the morale and performance of our personnel and our ability to hire new personnel.
Our common stock has declined in value below the exercise price of many options granted to employees pursuant to our stock option plans. Thus, the intended benefits of the stock options granted to our employees, the creation of performance and retention incentives, may not be realized. As a result, we may lose employees whom we would prefer to retain. As a result of these factors, our remaining personnel may seek employment with larger, more established companies or companies perceived as having less volatile stock prices.
Provisions in our agreements, charter documents, stockholder rights plan and Delaware law may deter takeover attempts, which could decrease the value of your shares.
Our certificate of incorporation and bylaws and Delaware law contain provisions that could make it more difficult for a third party to acquire us without the consent of our board of directors. Our board of directors has the right to issue preferred stock without stockholder approval, which could be used to dilute the stock ownership of a potential hostile acquirer. Delaware law imposes some restrictions on mergers and other business combinations between us and any holder of 15% or more of our outstanding common stock. In addition, we have adopted a stockholder rights plan that makes it more difficult for a third party to acquire us without the approval of our board of directors. These provisions apply even if the offer may be considered beneficial by some securityholders
Because technology changes rapidly, we may not be able to introduce our products in a timely enough fashion.
The semiconductor manufacturing industry is subject to rapid technological change and new system introductions and enhancements. We believe that our future success depends on our ability to continue to enhance our existing systems and their process capabilities, and to develop and manufacture in a timely manner new systems with improved process capabilities. We may incur substantial unanticipated costs to ensure product functionality and reliability early in our products life cycles. There can be no assurance that we will be successful in the introduction and volume manufacture of new systems or that we will be able to develop and introduce, in a timely manner, new systems or enhancements to our existing systems and processes which satisfy customer needs or achieve market adoption.
Some of our sales cycles are lengthy, exposing us to the risks of inventory obsolescence and fluctuations in operating results.
Sales of our systems depend, in significant part, upon the decision of a prospective customer to add new manufacturing capacity or to expand existing manufacturing capacity, both of which typically involve a significant capital commitment. We often experience delays in finalizing system sales following initial system qualification while the customer evaluates and receives approvals for the purchase of our systems and completes a new or expanded facility. Due to these and other factors, our systems typically have a lengthy sales cycle (often 12 to 18 months in the case of critical etch and deposition systems) during which we may expend substantial funds and management effort. Lengthy sales cycles subject us to a number of significant risks, including inventory obsolescence and fluctuations in operating results over which we have little or no control.
We may not be able to protect our intellectual property or obtain licenses for third parties intellectual property and therefore we may be exposed to liability for infringement or the risk that our operations may be adversely affected.
Although we attempt to protect our intellectual property rights through patents, copyrights, trade secrets and other measures, we may not be able to protect our technology adequately and competitors may be able to develop similar technology independently. Additionally, patent applications that we may file may not be issued and foreign intellectual property laws may not protect our intellectual property rights. There is also a risk that patents licensed by or issued to us will be challenged, invalidated or circumvented and that the rights granted thereunder will not provide competitive advantages to us. Furthermore, others may independently develop similar systems, duplicate our systems or design around the patents licensed by or issued to us.
Litigation could result in substantial cost and diversion of effort by us, which by itself could have a detrimental effect on our financial condition, operating results and cash flows. Further, adverse determinations in such litigation could result in our loss of proprietary rights, subject us to significant liabilities to third parties, require us to seek licenses from third parties or prevent us from manufacturing or selling our systems. In addition, licenses under third parties intellectual property rights may not be available on reasonable terms, if at all.
Our customers are concentrated and therefore the loss of a significant customer may harm our business.
Our top five customers accounted for 80.0%, 84.8% and 88.2% of our systems revenues in fiscal 2005, 2004 and 2003, respectively. Three customers each accounted for more than 10% of net systems sales in fiscal 2005. Although the composition of the group comprising our largest customers may vary from year to year, the loss of a significant customer or any reduction in orders by any significant customer, including reductions due to market, economic or competitive conditions in the semiconductor manufacturing industry, may have a detrimental effect on our business, financial condition, results of operations and cash flows. Our ability to increase our sales in the future will depend, in part, upon our ability to obtain orders from new customers, as well as the financial condition and success of our existing customers and the general economy, which is largely beyond our ability to control.
We are exposed to additional risks associated with international sales and operations.
International sales accounted for 70%, 67% and 66% of total revenue for fiscal 2005, 2004 and 2003, respectively. International sales are subject to certain risks, including the imposition of government controls, fluctuations in the U.S. dollar (which could increase the sales price in local currencies of our systems in foreign markets), changes in export license and other regulatory requirements, tariffs and other market barriers, political and economic instability, potential hostilities, restrictions on the export or import of technology, difficulties in accounts receivable collection, difficulties in managing representatives, difficulties in staffing and managing international operations and potentially adverse tax consequences. There can be no assurance that any of these factors will not have a detrimental effect on our operations, financial results and cash flows.
We generally attempt to offset a portion of our U.S. dollar denominated balance sheet exposures subject to foreign exchange rate remeasurement by purchasing forward currency contracts for future delivery. There can be no assurance that our future results of operations and cash flows will not be adversely affected by foreign currency fluctuations. In addition, the laws of certain countries in which our products are sold may not provide our products and intellectual property rights with the same degree of protection as the laws of the United States.
Evolving regulation of corporate governance and public disclosure may result in additional expenses and continuing uncertainty.
Changing laws, regulations and standard relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002, new SEC regulations and NASDAQ Market rules are creating uncertainty for public companies. We continually evaluate and monitor developments with respect to new and proposed rules and cannot predict or estimate the amount of the additional costs we may incur or the timing of such costs. These new or changed laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We are committed to maintaining high standards of corporate governance and public disclosure. As a result, we have invested resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and we may be harmed.
Our stock price is volatile and could result in a material decline in the value of your investment in Tegal.
We believe that factors such as announcements of developments related to our business, fluctuations in our operating results, sales of our common stock into the marketplace, failure to meet or changes in analysts expectations, general conditions in the semiconductor industry or the worldwide economy, announcements of technological innovations or new products or enhancements by us or our competitors, developments in patents or other intellectual property rights, developments in our relationships with our customers and suppliers, natural disasters and outbreaks of hostilities could cause the price of our common stock to fluctuate substantially. In addition, in recent years the stock market in general, and the market for shares of small capitalization stocks in particular, have experienced extreme price fluctuations, which have often been unrelated to the operating performance of affected companies. There can be no assurance that the market price of our common stock will not experience significant fluctuations in the future, including fluctuations that are unrelated to our performance.
Potential disruption of our supply of materials required to build our systems could have a negative effect on our operations and damage our customer relationships.
Materials delays have not been significant in recent years. Nevertheless, we procure certain components and sub-assemblies included in our systems from a limited group of suppliers, and occasionally from a single source supplier. For example, we depend on MECS Corporation, a robotic equipment supplier, as the sole source for the robotic arm used in all of our 6500 series systems. We currently have no existing supply contract with MECS Corporation, and we currently purchase all robotic assemblies from MECS Corporation on a purchase order basis. Disruption or termination of certain of these sources, including our robotic sub-assembly source, could have an adverse effect on our operations and damage our relationship with our customers.
Any failure by us to comply with environmental regulations imposed on us could subject us to future liabilities.
We are subject to a variety of governmental regulations related to the use, storage, handling, discharge or disposal of toxic, volatile or otherwise hazardous chemicals used in our manufacturing process. We believe that we are currently in compliance in all material respects with these regulations and that we have obtained all necessary environmental permits generally relating to the discharge of hazardous wastes to conduct our business. Nevertheless, our failure to comply with present or future regulations could result in additional or corrective operating costs, suspension of production, alteration of our manufacturing processes or cessation of our operations.
Special Note Regarding Forward Looking Statements
This Form 10-Q includes or incorporates by reference forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements, which are based on assumptions and describe our future plans, strategies and expectations, are generally identifiable by the use of the words anticipate, believe, estimate, expect, intend, project, or similar expressions. These forward-looking statements are subject to risks, uncertainties and assumptions about us. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this Form 10-Q are set forth under the caption Risk Factors and elsewhere in this prospectus and the documents incorporated by reference in this Form 10-Q. If one or more of these risks or uncertainties materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirely by the cautionary statements in this paragraph.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Our cash equivalents are principally comprised of money market accounts. As of June 30, 2005, we had cash and cash equivalents of $3,198. These accounts are subject to interest rate risk and may fall in value if market interest rates increase. We attempt to limit this exposure by investing primarily in short-term securities having a maturity of three months or less. Due to the nature of our cash and cash equivalents, we have concluded that there is no material market risk exposure.
We have foreign subsidiaries that operate and sell our products in various global markets. As a result, our cash flow and earnings are exposed to fluctuations in interest and foreign currency exchange rates. We attempt to limit these exposures through the use of various hedge instruments, primarily forward exchange contracts and currency option contracts (with maturities of less than three months) to manage our exposure associated with firm commitments and net asset and liability positions denominated in non-functional currencies. There have been no material changes regarding market risk since the disclosures made in our Form 10-K for the fiscal year ended March 31, 2005.
At June 30, 2005, the Company had forward exchange contracts maturing at various dates to exchange 195 million Japanese Yen into $1,800.
Item 4. Controls and Procedures
(a) Evaluation of Disclosure Controls and Procedures. Based on their evaluation as of a date at the end of the quarter covered by this quarterly report on Form 10-Q, the Companys Chief Executive Officer and Chief Financial Officer have concluded that the Companys disclosure controls and procedures (as defined in Rules 13a-14(c) under the Securities Exchange Act of 1934 are effective.
(b) Changes in Internal Controls. There were no significant changes in the Companys internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation.
PART II OTHER INFORMATION
Item 1. Legal Proceedings
Sputtered Films, Inc. v. Advanced Modular Sputtering, et al., filed in Santa Barbara County Superior Court.
On December 22, 2003, Sputtered Films, Inc. (SFI), a wholly owned subsidiary of the Company, filed an action against two former employees, Sergey Mishin and Rose Stuart-Curran, and a company they formed after leaving their employment with SFI named Advanced Modular Sputtering, Inc. (AMS). Sergey Mishin and Rose Stuart-Curran had each signed confidentiality and non-disclosure agreements regarding information obtained while employed by SFI. The action contains causes of action for specific performance, breach of contract, breach of the covenant of good faith and fair dealing, misappropriation of trade secrets, unfair competition, unfair business practices, interference with prospective economic advantage, conversion, unjust enrichment, and declaratory relief. These claims arise out of information SFI received evidencing that AMS possessed and used SFIs confidential, proprietary and trade secret drawings, specifications and technology to manufacture the sputtering tool marketed by AMS.
The parties stipulated to a protective order in order to commence the discovery phase, and SFI has responded to the discovery propounded by AMS. To date, however, SFI has been prevented from commencing discovery against AMS or other third party witnesses (in particular, Agilent Technologies, Inc.) due to the trial courts ruling that SFI has not yet described its trade secrets in sufficient detail pursuant to Code of Civil Procedure § 2019(d). In February 2005, the trial court ruled that SFI could proceed with discovery related to all causes of action, other than the trade secret cause of action. AMS petitioned the Court of Appeal for a writ reversing the trial courts order, which petition was denied. On June 8, 2005, the Supreme Court granted review of AMSs petition, and ordered the Court of Appeals to conduct the review. In light of the pending Court of Appeals review, the trial court vacated the previously set trial date and ordered a stay on all discovery by all parties.
Item 6. Exhibits
(a) Exhibits
Number | Exhibit |
---|---|
4.1 | Amendment to Rights Agreement dated January 18, 2005, filed as Exhibit 99.1 to Registrants Current Report on Form 8-K filed on July 19, 2005 and incorporated by reference herein. |
*10.1 | Restricted Stock Unit Award Agreement between Tegal Corporation and Brad Mattson, dated July 5, 2005, filed as Exhibit 10.2 to Registrants Current Report on Form 8-K filed on July 11, 2005 and incorporated by reference herein. |
*10.2 | Restricted Stock Unit Award Agreement between Tegal Corporation and Tom Mika, dated July 5, 2005, filed as Exhibit 10.4 to Registrants Current Report on Form 8-K filed on July 11, 2005 and incorporated by reference herein. |
31 | Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
32 | Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
_________________
* Indicates a management contract or compensatory plan or arrangement
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
TEGAL CORPORATION (Registrant) /s/ CHRISTINE T. HERGENROTHER Christine T. Hergenrother Chief Financial Officer |
Dated: August 12, 2005
EXHIBIT 31
CERTIFICATION OF THE
CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002
I, Thomas R. Mika, certify that:
1. | I have reviewed this quarterly report on Form 10-Q of Tegal Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-14(e)) for the registrant and we have: |
(a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; |
(c) | disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent function): |
(a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
(b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal controls over financial reporting. |
Date: August 12, 2005 | /s/ Thomas R. Mika
Chief Executive Officer and President |
CERTIFICATION OF THE
CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002
I, Christine Hergenrother, certify that:
1. | I have reviewed this quarterly report on Form 10-Q of Tegal Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-14(e)) for the registrant and we have: |
(a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; |
(c) | disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent function): |
(a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
(b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal controls over financial reporting. |
Date: August 12, 2005 | /s/ Christine T. Hergenrother
Chief Financial Officer |
EXHIBIT 32
CERTIFICATION PURSUANT
TO
SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)
In connection with the Quarterly Report of Tegal Corporation, a Delaware corporation (the Company), on Form 10-Q for the quarter ending June 30, 2005 as filed with the Securities and Exchange Commission (the Report), I, Thomas R. Mika, President and Chief Executive Officer of the Company, certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), that to my knowledge:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
/s/ Thomas R. Mika
Chief Executive Officer
and President
August 12, 2005
CERTIFICATION PURSUANT
TO
SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)
In connection with the Quarterly Report of Tegal Corporation, a Delaware corporation (the Company), on Form 10-Q for the quarter ending June 30, 2005 as filed with the Securities and Exchange Commission (the Report), I, Christine Hergenrother, Chief Financial Officer of the Company, certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), that to my knowledge:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
/s/ Christine
Hergenrother
Chief Financial Officer
August
12, 2005